<scp>E</scp>pac and the high affinity rolipram binding conformer of <scp>PDE</scp>4 modulate neurite outgrowth and myelination using an <i>in vitro</i> spinal cord injury model

Abstract

PDE4 inhibitors targeted at the HARBS conformer or Epac agonists may provide promising novel targets for the treatment of SCI. Our study demonstrates the differential mechanisms of action of these compounds, as well as the benefit of a combined pharmacological approach and highlighting potential promising targets for the treatment of SCI. These findings need to be confirmed in vivo.